Slide 1: Investor Presentation | May 2025
Investor Presentation | May 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Harrow's Ophthalmic Pharmaceutical Brands
Harrow’s Ophthalmic Pharmaceutical Brands |3| Investor Presentation | May 2025
Slide 4: Investment Highlights
Investment Highlights 2025 Revenue expected to be more than $280 million, including: 1. IHEEZO – launched May of 2023; growth accelerating in 2025 and beyond 2. VEVYE – launched January 2024; large market category-leading potential 3. TRIESENCE – re-launched in October 2024; strong customer affinity
Slide 5: Key Financial Metrics (in thousands)
Key Financial Metrics (in thousands) ‘25 Guidance $40,327 > $280,000 $199,614 $28,119 $130,193 $13,017 $88,595 $11,378 $72,476 $48,871 $5,715 $47,813 1Q25 20 21 22 23 24 25 20 21 22 23 24 Consolidated Revenues Adjusted EBITDA(1) (1) Adjusted EBITDA is defined as net income (loss), excluding the effe
Slide 6: IHEEZO
IHEEZO IHEEZO Quarterly Customer Unit Demand(1) (May 2023 launch) 49,130 38,940 34,468 29,991 20,886 15,096 6,435 493 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 (1) Customer Unit Demand reflects the number of units purchased by surgery centers, clinic/group practices, and physic
Slide 7: VEVYE
VEVYE VEVYE Quarterly Prescriptions (January 2024 launch) (Based on IQVIA Xponent data, including PhilRx and Asembia)(1) 75,409 72,017 53,065 35,150 8,730 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 (1) As of 2Q25, Harrow pharmacy partners have discontinued reporting VEVYE prescription data to third-par
Slide 8: TRIESENCE
TRIESENCE Description:(1) • The only FDA-approved preservative-free synthetic corticosteroid with separate reimbursement in all traditional settings of care • Indications: • Visualization During Vitrectomy (420,000 procedures per year) • Posterior Uveitis (100,000 diagnoses per year) Supply Chain: •
Slide 9: Anterior Segment Products
Anterior Segment Products Portfolio includes: • Steroids, NSAIDs, and Anti-inflammatories • An OTC preservative-free lubricant • An Antihistamine, and Antibiotics • The only FDA-approved Antifungal • Medication to treat vernal keratoconjunctivitis, a rare disease • Anti-glaucoma medications |9| Inve
Slide 10: ImprimisRx
ImprimisRx Revenues* (Dollars in thousands) $82,013 $83,499 $79,935 $69,104 $48,475 $20,051 20 21 22 23 24 1Q25 *Excludes revenue From DEXYCU® in all years; 2023 revenues reflect sale of Company’s non-ophthalmic business. ImprimisRx’s revenue is for compounded products, which are not FDA-approved |
Slide 11: Equity Ownership – Melt Pharmaceuticals
Equity Ownership – Melt Pharmaceuticals Melt Pharmaceuticals is a former subsidiary of Harrow MELT-300 is a non-IV and non-opioid sublingual sedation drug candidate for short-duration medical procedures MELT-300 is patented in the U.S. and key global markets Harrow Others Potential impact in >100 mi
Slide 12: Commitment to Supporting Mission Trips
Commitment to Supporting Mission Trips See Intl Eye Doctors of Lancaster Nevis Eye Care Health in Sight Missions (Honduras) (Africa) (West Indies) (Honduras) April 2024 October 2024 November 2024 February 2025 During 2024, Harrow’s donations helped approximately To date, in 2025, Harrow has committe
Slide 13: Harrow contact details
1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 www.Harrow.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737